Autoantibodies against other 2 autoantigens namely CMYC and MUC1 were selected as biomarkers for panel assay based on the performance of in-house developed ELISA in distinguishing canine mammary tumours from healthy controls (Supplementary Table S8). This evidence concerns the gene MYC and breast cancer.